Beta-blockers in hypertension

American Journal of Cardiology

Volumn 106, Issue 12, 2010, Pages 1819-1825

  Ram, C Venkata S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LABETALOL; LIPID; LOSARTAN; METOPROLOL; NEBIVOLOL; PROPRANOLOL; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HEART FAILURE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT INDICATION; VASCULAR RESISTANCE;

EID: 78649691243     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.08.023     Document Type: Review

References (55)

1. W.H. Frishman A historical perspective on the development of β-adrenergic blockers J Clin Hypertens 9 suppl 2007 19 27
2. H. Black Do beta-blockers have a role in hypertension any longer? Medscape Cardiol 10 2006 http://cme.medscape.com/viewarticle/542689 Accessed September 8, 2008
3. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr, and E.J. Roccella Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252 (Pubitemid 37553153)
4. National Institute for Health and Clinical Excellence Hypertension: Management of Hypertension in Adults in Primary Care: Pharmacological Update NICE Clinical Guideline 34 2006 National Institute for Health and Clinical Excellence London 8
5. L.H. Lindholm, B. Carlberg, and O. Samuelsson Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis Lancet 366 2005 1545 1553
6. S. Bangalore, S. Parkar, E. Grossman, and F.H. Messerli A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus Am J Cardiol 100 2007 1254 1262
7. G. Beevers, G.Y.H. Lip, and E. O'Brien ABC of hypertension: the pathophysiology of hypertension BMJ 322 2001 912 916
8. B. Neal, S. MacMahon, N. Chapman Blood Pressure Lowering Treatment Trialists' Collaboration Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials Lancet 355 2000 1955 1964
9. L. Wilhelmsen, G. Berglund, D. Elmfeldt, T. Fitzsimons, H. Holzgreve, J. Hosie, P.E. Hornkvist, K. Pennert, J. Tuomilehto, and H. Wedel Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial J Hypertens 5 1987 561 572
10. Medical Research Council Working Party MRC trial of treatment of mild hypertension: principal results Br Med J (Clin Res Ed) 291 1985 97 104
11. J.G. Wang, and J.A. Staessen Conventional therapy and newer drug classes for cardiovascular protection in hypertension J Am Soc Nephrol 13 suppl 2002 S208 S215
12. F.H. Messerli, and E. Grossman β-blockers in hypertension: is carvedilol different? Am J Cardiol 93 suppl 2004 7B 12B
13. M. Le Brocq, S.J. Leslie, P. Milliken, and I.L. Megson Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities Antioxid Redox Signal 10 2008 1631 1674
14. J. Davies, E. Carr, M. Band, A. Morris, and A. Struthers Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? J Renin Angiotensin Aldosterone Syst 6 2005 151 153
15. Z. Dhakam, C.M.Yasmin McEniery, J.R. Cockcroft, M.J. Brown, and I.B. Wilkinson Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity Am J Hypertens 19 2006 214 219
16. B. Williams, P.S. Lacy, S.M. Thom, K. Cruickshank, A. Stanton, D. Collier, A.D. Hughes, H. Thurston, and M. O'Rourke Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study Circulation 113 2006 1213 1225
17. T. Morgan, J. Lauri, D. Bertram, and A. Anderson Effect of different antihypertensive drug classes on central aortic pressure Am J Hypertens 17 2004 118 123
18. K. Hirata, C. Vlachopoulos, A. Adji, and M.F. O'Rourke Benefits from angiotensin-converting enzyme inhibitor "beyond blood pressure lowering": beyond blood pressure or beyond the brachial artery? J Hypertens 23 2005 551 556
19. M. Terai, M. Ohishi, N. Ito, T. Takagi, Y. Tatara, M. Kaibe, N. Komai, H. Rakugi, and T. Ogihara Comparison of arterial functional evaluations as a predictor of cardiovascular events in hypertensive patients: the Non-Invasive Atherosclerotic Evaluation in Hypertension (NOAH) study Hypertens Res 31 2008 1135 1145
20. M.E. Pedersen, and J.R. Cockcroft The vasodilatory beta-blockers Curr Hypertens Rep 9 2007 269 277
21. N. Toda Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics Pharmacol Ther 100 2003 215 234
22. E.P. MacCarthy, and S.S. Bloomfield Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects Pharmacotherapy 3 1983 193 219
23. J. Varon Treatment of acute severe hypertension: current and newer agents Drugs 68 2008 283 297
24. M.E. Davidov, G.D. Moir, M.P. Poland, J. Maloy, and M. Medakovic Monotherapy with labetalol in the treatment of mild hypertension: a double-blind study Am J Med 75 1983 47 53
25. I. Darmansjah, A. Setiawati, P. Prabowo, E. Sukandar, I. Parsoedi, Ardaya, B. Bahry, J. Jusman, and E. Anggraeni A dose-ranging study of labetalol in moderate to moderately severe hypertension Int J Clin Pharmacol Ther 33 1995 226 231
26. W.B. Applegate, N. Borhani, V. DeQuattro, P.M. Kaihlanen, S. Oishi, D.L. Due, and M.A. Sirgo Comparison of labetalol versus enalapril as monotherapy in elderly patients with hypertension: results of 24-hour ambulatory blood pressure monitoring Am J Med 90 1991 198 205
27. N.K. Prasad Labetalol and nifedipine in the management of essential hypertension J Indian Med Assoc 88 1990 188 189
28. T. Morgan, R. Snowden, and L. Butcher Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance J Cardiovasc Pharmacol 10 suppl 1987 S124 S129
29. K. Weber, T. Bohmeke, R. van der Does, and S.H. Taylor Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients Cardiovasc Drugs Ther 10 1996 113 117
30. L.S. Henderson, D.M. Tenero, C.A. Baidoo, A.M. Campanile, A.H. Harter, D. Boyle, and T.M. Danoff Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension Am J Cardiol 98 suppl 2006 17L 26L
31. M.A. Weber, G.L. Bakris, E.A. Tarka, M. Iyengar, R. Fleck, and D.A. Sica Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension J Clin Hypertens (Greenwich) 8 2006 840 849
32. E. Arosio, S. De Marchi, M. Prior, M. Zannoni, and A. Lechi Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress J Hypertens 20 2002 1793 1797
33. R.J. Weiss, M.A. Weber, A.A. Carr, and W.A. Sullivan A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel β-blocker, in patients with mild to moderate hypertension J Clin Hypertens (Greenwich) 9 2007 667 676
34. T.J. Cleophas, R. Agrawal, A. Lichtenthal, W. Makel, and F. Fici Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients Am J Ther 13 2006 192 197
35. A.C. Schmidt, C. Graf, K. Brixius, and J. Scholze Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study Clin Drug Investig 27 2007 841 849
36. I. Czuriga, I. Riecansky, J. Bodnar, T. Fulop, V. Kruzsicz, E. Kristof, I. Edes The NI Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS) Cardiovasc Drugs Ther 17 2003 257 263
37. E.A. Rosei, D. Rizzoni, S. Comini, and G. Boari Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study Blood Press Suppl 1 2003 30 35
38. L.M. Van Bortel, F. Fici, and F. Mascagni Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis Am J Cardiovasc Drugs 8 2008 35 44
39. B.M. Egan, J. Basile, R.J. Chilton, and J.D. Cohen Cardioprotection: the role of beta-blocker therapy J Clin Hypertens (Greenwich) 7 2005 409 416
40. J.T. Wright Jr, G.L. Bakris, D.S.H. Bell, V. Fonseca, R.E. Katholi, J.B. McGill, F.H. Messerli, R.A. Phillips, P. Raskin, F.K. Holdbrook, M.A. Lukas, and M. Iyengar Lowering blood pressure with β-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI trial J Clin Hypertens (Greenwich) 9 2007 842 849
41. G.L. Bakris, V. Fonseca, R.E. Katholi, J.B. McGill, F.H. Messerli, R.A. Phillips, P. Raskin, J.T. Wright Jr, R. Oakes, M.A. Lukas, K.M. Anderson, and D.S. Bell Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial JAMA 292 2004 2227 2236
42. C. Rosendorff, H.R. Black, C.P. Cannon, B.J. Gersh, J. Gore, J.L. Izzo Jr, N.M. Kaplan, C.M. O'Connor, P.T. O'Gara, and S. Oparil Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation 115 2007 2761 2788
43. M. Galderisi, and A. D'Errico Beta-blockers and coronary flow reserve: the importance of a vasodilatory action Drugs 68 2008 579 590
44. β-Blocker Heart Attack Trial Research Group A randomized trial of propranolol in patients with acute myocardial infarction I. Mortality results JAMA 247 1982 1707 1714
45. J.E. Otterstad, and I. Ford The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail 4 2002 501 506
46. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction N Engl J Med 304 1981 801 807
47. J. Herlitz, B.W. Karlson, and A. Hjalmarson Ten year mortality in relation to original size of myocardial infarct: results from the Gothenburg metoprolol study Br Heart J 71 1994 238 241
48. H.J. Dargie, W. Colucci, I. Ford, J.L.L. Sendon, W. Remme, N. Sharpe, A. Blank, and T.L. Holcslaw Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 357 2001 1385 1390
49. W. Rosamond, K. Flegal, K. Furie, A. Go, K. Greenlund, N. Haase, S.M. Hailpern, M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lloyd-Jones, M. McDermott, J. Meigs, C. Moy, G. Nichol, C. O'Donnell, V. Roger, P. Sorlie, J. Steinberger, T. Thom, M. Wilson, and Y. Hong Heart disease and stroke statistics2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 2008 e25 e146
50. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G. Ganiats, M. Jessup, M.A. Konstam, D.M. Mancini, K. Michl, J.A. Oates, P.S. Rahko, M.A. Silver, L.W. Stevenson, C.W. Yancy, E.M. Antman, S.C. Smith Jr, C.D. Adams, J.L. Anderson, D.P. Faxon, V. Fuster, J.L. Halperin, L.F. Hiratzka, A.K. Jacobs, R. Nishimura, J.P. Ornato, R.L. Page, and B. Riegel ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society Circulation 112 2005 e154 e235
51. G.C. Fonarow, W.T. Abraham, N.M. Albert, W.G. Stough, M. Gheorghiade, B.H. Greenberg, C.M. O'Connor, J.L. Sun, C.W. Yancy, and J.B. Young Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program J Am Coll Cardiol 52 2008 190 199
52. P.A. Poole-Wilson, K. Swedberg, J.G.F. Cleland, A. Di Lenarda, P. Hanrath, M. Komajda, J. Lubsen, B. Lutiger, M. Metra, W.J. Remme, C. Torp-Pedersen, A. Scherhag, and A. Skene Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13
53. C. Torp-Pedersen, P.A. Poole-Wilson, K. Swedberg, J.G. Cleland, A. Di Lenarda, P. Hanrath, M. Komajda, B. Lutiger, M. Metra, W.J. Remme, A. Scherhag, and A. Skene Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failureCOMET Am Heart J 149 2005 370 376
54. D. Dobre, D.J. van Veldhuisen, G. Mordenti, M. Vintila, F.M. Haaijer-Ruskamp, A.J. Coats, P.A. Poole-Wilson, and M.D. Flather Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors With Heart Failure (SENIORS) trial Am Heart J 154 2007 109 115
55. M.D. Flather, M.C. Shibata, A.J.S. Coats, D.J. Van Veldhuisen, A. Parkhomenko, J. Borbola, A. Cohen-Solal, D. Dumitrascu, R. Ferrari, P. Lechat, J. Soler-Soler, L. Tavazzi, L. Spinarova, J. Toman, M. Bohm, S.D. Anker, S.G. Thompson, and P.A. Poole-Wilson Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 2005 215 225